1
|
Scantling D, Fischer C, Gruner R, Teichman A, McCracken B, Eakins J. The role of delayed head CT in evaluation of elderly blunt head trauma victims taking antithrombotic therapy. Eur J Trauma Emerg Surg 2017; 43:741-746. [PMID: 28439613 DOI: 10.1007/s00068-017-0793-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2017] [Accepted: 04/18/2017] [Indexed: 10/19/2022]
Abstract
INTRODUCTION Increasing active longevity has created an increasing surge of elderly trauma patients. The majority of these patients suffer blunt trauma and many are taking antithrombotic agents. The literature is mixed regarding the utility of routine repeat head CT in patients taking antithrombotic medications with a GCS of 15 and initial negative head CT. We hypothesized that scheduled delayed CT head 12 h after admission (D-CTH) in elderly blunt trauma victims would not identify clinically significant new hemorrhages or change management. METHODS A retrospective chart review using our institutional trauma registry of patients ≥65 years sustaining blunt head injuries from 2010 to 2012 was performed. By hospital protocol, all such patients on antithrombotic therapy receive a routine D-CTH. All of these patients were included. Demographics, injuries, medications, laboratory values, LOS, mental status, and management were analyzed. RESULTS Of the 234 patients meeting inclusion criteria, 8 initially were identified as having D-ICH. Upon further review, five patients had the same findings on both initial and delayed CT scans and one patient was determined to actually have had a hemorrhage stroke. Ultimately, only two patients (0.85%, 95% CI 0.1-3.1%) had new ICH discovered on D-CTH. None of the patients on warfarin demonstrated any new injury on D-CTH (95% CI ≤ 4.6%). Only one patient taking aspirin as a sole agent had a delayed injury on D-CTH (1.1%, 95% CI 0-4.2%). The remaining patient was taking a combination of aspirin and clopidogrel representing 2.2% of 45 patients on combination therapy (95% CI 0.1-11.8%). Only two patients taking a direct thrombin inhibitor (dabigatran) met inclusion criteria and neither endured a bleed (95% CI ≤ 77.6%). Further analysis revealed no cases with clinical changes or surgical intervention for new ICH on delayed imaging. No inference could be made to predict which patients would suffer D-ICH. CONCLUSIONS D-CTH in elderly trauma patients taking antithrombotic agents shows no statistically significant or clinical benefit for diagnosing delayed intracranial hemorrhage after minor head injury. In those with delayed imaging showing new ICH, management was not significantly altered. Not enough data were available to predict which patients would develop D-ICH, even if asymptomatic.
Collapse
Affiliation(s)
- D Scantling
- Hahnemann University Hospital, Drexel University College of Medicine, 215 N 15th St MS 413, Philadelphia, PA, 19102, USA.
| | - C Fischer
- Hahnemann University Hospital, Drexel University College of Medicine, 215 N 15th St MS 413, Philadelphia, PA, 19102, USA
| | - R Gruner
- Hahnemann University Hospital, Drexel University College of Medicine, 215 N 15th St MS 413, Philadelphia, PA, 19102, USA
| | - A Teichman
- Hahnemann University Hospital, Drexel University College of Medicine, 215 N 15th St MS 413, Philadelphia, PA, 19102, USA
| | - B McCracken
- Hahnemann University Hospital, Drexel University College of Medicine, 215 N 15th St MS 413, Philadelphia, PA, 19102, USA
| | - J Eakins
- AtlantiCare Regional Medical Center, 1925 Pacific Avenue, Atlantic City, NJ, 08401, USA
| |
Collapse
|
2
|
Yeh CC, Wang LJ, McGarrigle JJ, Wang Y, Liao CC, Omami M, Khan A, Nourmohammadzadeh M, Mendoza-Elias J, McCracken B, Marchese E, Barbaro B, Oberholzer J. Effect of Manufacturing Procedures on Human Islet Isolation From Donor Pancreata Standardized by the North American Islet Donor Score. Cell Transplant 2016; 26:33-44. [PMID: 27524672 DOI: 10.3727/096368916x692834] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
This study investigates manufacturing procedures that affect islet isolation outcomes from donor pancreata standardized by the North American Islet Donor Score (NAIDS). Islet isolations performed at the University of Illinois, Chicago, from pancreata with NAIDS ≥65 were investigated. The research cohort was categorized into two groups based on a postpurification yield either greater than (group A) or less than (group B) 400,000 IEQ. Associations between manufacturing procedures and islet isolation outcomes were analyzed using multivariate logistic or linear regressions. A total of 119 cases were retrieved from 630 islet isolations performed since 2003. Group A is composed of 40 cases with an average postpurified yield of 570,098 IEQ, whereas group B comprised 79 cases with an average yield of 235,987 IEQ. One third of 119 cases were considered successful islet isolations that yielded >400,000 IEQ. The prepurified and postpurified islet product outcome parameters were detailed for future reference. The NAIDS (>80 vs. 65-80) [odds ratio (OR): 2.91, 95% confidence interval (CI): 1.27-6.70], cold ischemic time (≤10 vs. >10 h) (OR: 3.68, 95% CI: 1.61-8.39), and enzyme perfusion method (mechanical vs. manual) (OR: 2.38, 95% CI: 1.01-5.56) were independent determinants for postpurified islet yield ≥400,000 IEQ. The NAIDS (>80, p < 0.001), cold ischemic time (≤10 h, p < 0.05), increased unit of collagenase (p < 0.01), and pancreatic duct cannulation time (<30 min, p < 0.01) all independently correlated with better islet quantity parameters. Furthermore, cold ischemic time (≤10 h, p < 0.05), liberase MTF (p < 0.001), increased unit of collagenase (p < 0.05), duct cannulation time (<30 min, p < 0.05), and mechanical enzyme perfusion (p < 0.05) were independently associated with better islet morphology score. Analysis of islet manufacturing procedures from the pancreata with standardized quality is essential in identifying technical issues within islet isolation. Adequate processing duration in each step of islet isolation, using liberase MTF, and mechanical enzyme perfusion all affect isolation outcomes.
Collapse
|
3
|
Marchese E, Rodeghier C, Monson RS, McCracken B, Shi T, Schrock W, Martellotto J, Oberholzer J, Danielson KK. Enumerating β-Cells in Whole Human Islets: Sex Differences and Associations With Clinical Outcomes After Islet Transplantation. Diabetes Care 2015; 38:e176-7. [PMID: 26384388 PMCID: PMC4613918 DOI: 10.2337/dc15-0723] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2015] [Accepted: 08/17/2015] [Indexed: 02/03/2023]
Affiliation(s)
- Enza Marchese
- Division of Transplant Surgery, University of Illinois at Chicago, Chicago, IL
| | - Caitlin Rodeghier
- Division of Transplant Surgery, University of Illinois at Chicago, Chicago, IL
| | - Rebecca S Monson
- Division of Transplant Surgery, University of Illinois at Chicago, Chicago, IL
| | - Benjamin McCracken
- Division of Transplant Surgery, University of Illinois at Chicago, Chicago, IL
| | - Tingqi Shi
- Division of Transplant Surgery, University of Illinois at Chicago, Chicago, IL
| | - Wesley Schrock
- Division of Transplant Surgery, University of Illinois at Chicago, Chicago, IL
| | - Joan Martellotto
- Division of Transplant Surgery, University of Illinois at Chicago, Chicago, IL
| | - Jose Oberholzer
- Division of Transplant Surgery, University of Illinois at Chicago, Chicago, IL
| | - Kirstie K Danielson
- Division of Transplant Surgery, University of Illinois at Chicago, Chicago, IL Division of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL
| |
Collapse
|
4
|
Villalona-Calero M, Goel S, Schaaf L, McCracken B, Desai K, Cropp G, Kersey K, Johnson R, Hannah A, Mani S. 634 POSTER Safety and Pharmacokinetic (PK) Trial of KOS-1584, a Novel Analog of Epothilone D. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)70639-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
5
|
Villalona-Calero M, Goel S, Schaaf L, McCracken B, Desai K, Cropp G, Zhou Y, Johnson RG, Hannah AL, Mani S. First-in-human phase I trial of a novel epothilone, KOS-1584. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.2003] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2003 Background: KOS-1584 (9,10-didehydroepothilone D) was discovered as part of a screening program to develop a new generation of epothilones with higher potency and an improved pharmacologic/pharmacokinetic (PK) profile. Epothilones stabilize microtubule polymerization, inducing rapid G2/M arrest and apoptosis. Antitumor activity of KOS-1584 (Chou et al 2003) is approximately 3–12 fold more potent when compared to the structurally related Epothilone D. KOS-1584 demonstrates enhanced tumor tissue penetration and reduced exposure to selected tissues (including CNS). We report the results of the initial dose-escalation trial in which KOS-1584 was administered to pts with advanced solid malignancies. Methods: Define the MTD, toxicity profile and PK of KOS-1584 when administered via 3-hour infusion every 3 weeks. PK was determined after the 1st and 2nd infusion. Pharmacodynamics were assessed by serial sampling of PBMCs for microtubule bundle formation. Results: 27 pts (17 F; median age 60; median ECOG PS 1; median prior regimens 3, range 0–7) enrolled in 8 dose levels (between 0.8 - 11.3 mg/m2). To date, no Cycle 1 DLT has been seen. Toxicities (n=24) did not show obvious dose dependency; common toxicity (Grade 1–2) included gastrointestinal (diarrhea, constipation, nausea), fatigue, and ↑AST. Drug-related Grade 3 toxicity: constipation, fatigue and ↑AST (1 each). Drug-related neurotoxicity was not notable. PK/parent (n=25): t½ 17.7 ± 4.6h, Vz 741±330 L and CL 30.2± 16.5 L/h. At 8.5 mg/m2 Cmax 78 ± 29 ng/mL; AUCtot 631 ± 337 ng*h/mL. Cmax and AUCtot increased linearly with dose over the range tested. Vz is ∼5-fold and t½ 2-fold higher than that of Epothilone D. Dose dependent increases in microtubule bundle formation were observed (8.5 mg/m2: 40–50% at end of infusion, compared to 60–65% for ixabepilone and 50–60% for Epothilone D using the same assay at their phase 2 dose). A sigmoidal Emax model described the relationship between plasma concentration and microtubule bundle formation. Activity consisted of 4 pts with extended stable disease (6 cycles leiomyosarcoma and ovarian cancer; 5 cycles colon cancer; a 2nd patient with ovarian cancer is active at 5 cycles). Of these, 3 had document progressive disease prior to study. Conclusions: Accrual is continuing in order to define the optimal dose on the 3-week regimen. [Table: see text]
Collapse
Affiliation(s)
- M. Villalona-Calero
- Ohio State University, Columbus, OH; Albert Einstein Hospital, Bronx, NY; Kosan Biosciences, Inc., Hayward, CA
| | - S. Goel
- Ohio State University, Columbus, OH; Albert Einstein Hospital, Bronx, NY; Kosan Biosciences, Inc., Hayward, CA
| | - L. Schaaf
- Ohio State University, Columbus, OH; Albert Einstein Hospital, Bronx, NY; Kosan Biosciences, Inc., Hayward, CA
| | - B. McCracken
- Ohio State University, Columbus, OH; Albert Einstein Hospital, Bronx, NY; Kosan Biosciences, Inc., Hayward, CA
| | - K. Desai
- Ohio State University, Columbus, OH; Albert Einstein Hospital, Bronx, NY; Kosan Biosciences, Inc., Hayward, CA
| | - G. Cropp
- Ohio State University, Columbus, OH; Albert Einstein Hospital, Bronx, NY; Kosan Biosciences, Inc., Hayward, CA
| | - Y. Zhou
- Ohio State University, Columbus, OH; Albert Einstein Hospital, Bronx, NY; Kosan Biosciences, Inc., Hayward, CA
| | - R. G. Johnson
- Ohio State University, Columbus, OH; Albert Einstein Hospital, Bronx, NY; Kosan Biosciences, Inc., Hayward, CA
| | - A. L. Hannah
- Ohio State University, Columbus, OH; Albert Einstein Hospital, Bronx, NY; Kosan Biosciences, Inc., Hayward, CA
| | - S. Mani
- Ohio State University, Columbus, OH; Albert Einstein Hospital, Bronx, NY; Kosan Biosciences, Inc., Hayward, CA
| |
Collapse
|
6
|
Lu Q, Caputo F, McCracken B, Watkins A, Xu DZ, Deitch EA. THE RELATIVE ROLE OF CASPASE-DEPENDENT AND INDEPENDENT APOPTOSIS OF ENDOTHELIAL AND PULMONARY EPITHELIAL CELLS, INDUCED BY T/HS LYMPH, VARIES BY CELLTYPE. Shock 2006. [DOI: 10.1097/00024382-200606001-00166] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|